Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Novartis
University Health Network, Toronto
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
H. Lee Moffitt Cancer Center and Research Institute
Novartis
National Cancer Institute (NCI)
Augusta University
Novartis
Center for International Blood and Marrow Transplant Research
Takeda
Center for International Blood and Marrow Transplant Research
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Groupe Francophone des Myelodysplasies
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Center for International Blood and Marrow Transplant Research
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Baylor College of Medicine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Petersburg State Pavlov Medical University
Centre Leon Berard
M.D. Anderson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
European LeukemiaNet
Novartis
Memorial Sloan Kettering Cancer Center
Obafemi Awolowo University
Novartis
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
Medical College of Wisconsin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center